Octopuses Fall For The Classic Fake Arm Trick – Just Like We Do
When scientists in Japan pinched an artificial appendage during experiments, octopuses recoiled in defense – swimming away, suddenly changing their color, or retracting their arms, as if they'd really been hurt.
The reaction is not proof that cephalopods are dim-witted or easily tricked – quite the contrary.
The findings are a first and they suggest that octopuses are highly intelligent creatures that feel a sense of responsibility over their appendages.
Related:
Even we humans fall for the body transfer illusion, which is used to study an animal's sense of body ownership. The trick was originally reported in our own species in 1998, and more recently in monkeys and mice.
Now, it seems invertebrates can be fooled too.
That's remarkable, as octopus arms are controlled by a nervous system like no other.
"Our findings suggest, like humans, octopuses have a multisensory representation of their body," the study authors conclude.
To figure out how octopuses feel about their own bodies, animal behavior scientists Sumire Kawashima and Yuzuru Ikeda of the University of the Ryukyus placed plain-body night octopuses (Callistoctopus aspilosomatis) in a tank for a series of experiments.
During the trials, one of the octopus arms was hidden from sight by a screen. A fake arm made of soft gel was then placed in front of the screen.
Scientists stroked both the fake limb and the hidden limb simultaneously. Immediately after, researchers pinched the fake arm.
Within seconds, the octopus responded as if it had been attacked, though it wasn't physically hurt.
That might seem like an overreaction, but even humans who are prepared can fall for this trick. If one of our hands is placed behind a screen and a fake hand placed in front, we can be made to 'feel' the fake hand.
Our brains are essentially fooling us into thinking the touch we are feeling on our real hand is related to the touch we are seeing. Once that link is established, our brain automatically takes ownership of the fake hand.
If we see the fake hand being prodded, then we also feel it.
The reason we fall for this illusion is complicated, but essentially, it's because our brains are exceptional at rapidly integrating perceptions of touch, vision, and proprioception (which is the sense of where our bodies are in space).
Octopus brains are apparently also skilled in this respect.
These marine mollusks have extremely flexible, incredibly dexterous arms, with approximately 500 million neurons running through each.
All eight limbs can make decisions independent of the brain, and they can even 'taste' with their finger-like suckers.
Similar to humans, however, it seems that the octopus brain also prefers visual information over other senses, like touch, taste, or proprioception.
This makes it possible for the creature to adopt a limb they see that isn't actually theirs.
"These results suggest that the basic perceptual rules that determine body ownership in octopuses are similar to those of mammals," argue Kawashima and Ikeda.
"These findings in the octopus, which has a complex nervous system that has developed independently of vertebrates, may be an important model for studying the evolution of the sense of body ownership."
The correspondence was published in Current Biology.
Related News
Bone-Eating Worms Have Lurked in The Ocean For 100 Million Years
Ancient Voice Box Finally Reveals How Dinosaurs May Have Sounded
Stunning Grand Canyon Fossils Reveal Evolution's Weird Experiments
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
5 hours ago
- Medscape
Low FT3 Levels Predict Risk for Nerve Damage in Diabetes
TOPLINE: In euthyroid patients with type 2 diabetes (T2D), relatively higher free triiodothyronine (FT3) levels within the normal range were linked to a lower risk for diabetic peripheral neuropathy and better nerve function. METHODOLOGY: In euthyroid patients with T2D, lower FT3 levels within the normal range can worsen glucose and lipid metabolism and increase the risk for nephropathy and retinopathy, but the association of FT3 levels with peripheral neuropathy remains unclear. Researchers in China examined the relationship between FT3 levels and diabetic peripheral neuropathy in 1422 euthyroid patients with T2D (mean age, 58.04 years; 33.97% women) who underwent electromyography during hospitalization. Participants were considered euthyroid if their thyroid-stimulating hormone level was 0.25-5.5 IU/mL, free thyroxine level was 9.0-25.5 pmol/L, and FT3 level was 2.5-7.0 pmol/L. A diagnosis of diabetic peripheral neuropathy was made in those who showed neuropathic symptoms (neuropathic pain, paresthesias, numbness, sensory distortion, unsteadiness, or falls) and signs (pain sensation abnormalities, vibration sensation abnormalities, loss of the ankle reflex, touch/pressure sensation abnormalities, or temperature sensation abnormalities) during or after confirmed diabetes diagnosis. Nerve conduction studies of the distal limbs (median, ulnar, common peroneal, sural, and superficial peroneal nerves) were conducted in all participants, and distal motor and sensory nerve latencies, action potential amplitudes, and conduction velocities of motor and sensory nerves were recorded. TAKEAWAY: Among all participants with T2D, the 519 who were diagnosed with diabetic peripheral neuropathy showed significantly lower serum FT3 levels than those without the condition (P < .001). The risk for diabetic peripheral neuropathy was reduced in participants with FT3 levels between 4.3 and 4.7 pmol/L (odds ratio [OR], 0.57; 95% CI, 0.39-0.81) and 4.7 and 7.0 pmol/L (OR, 0.33; 95% CI, 0.21-0.52) compared with those with FT3 levels between 2.5 and 3.8 pmol/L. Participants with neuropathy had slower, weaker nerve responses and longer latencies than those without, with higher FT3 levels in patients with diabetic peripheral neuropathy being linked to faster nerve conduction and shorter latencies. A Mendelian randomization analysis using the ThyroidOmics Consortium and the UK Biobank genome-wide association study data also indicated a causal relationship between low FT3 levels and the risk for diabetic peripheral neuropathy (inverse variance weighted β = -0.655; P = .035). IN PRACTICE: 'Within the normal range, a relatively high level of FT3 (> 4.3 pmol/L) was associated with a reduced risk of DPN [diabetic peripheral neuropathy]. Thyroid hormones may be beneficial for patients with DPN if their FT3 levels are near the low end of the normal range,' the authors of the study wrote. SOURCE: This study was led by Bing'er Xu, Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China. It was published online in the Journal of Clinical Endocrinology and Metabolism. LIMITATIONS: This study was limited by its single-center design and focused on hospitalized patients with T2D in Shanghai. It measured only specific peripheral nerves' conduction parameters. The Mendelian randomization analysis was conducted only in Europeans, requiring validation in other ethnic populations. DISCLOSURES: This study received support from the National Science and Technology Major Project, the National Natural Science Foundation of China, the Science and Technology Commission of Shanghai Municipality, and other sources. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
5 hours ago
- Yahoo
Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033
The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 billion by 2033 with a CAGR of 12.99%. Key technologies like digital PCR, liquid biopsy, and next-generation sequencing are driving growth amid rising cancer rates in China, India, and Japan. While high costs and a shortage of skilled professionals challenge expansion, collaborations and innovations are enhancing molecular diagnostic adoption. Strategic efforts, including AI, reimbursement standardization, and genomic literacy programs, aim to advance precision oncology in the APAC region, addressing barriers and harnessing growth opportunities. Asia-Pacific Molecular Oncology Diagnostics Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033" has been added to Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1.54 billion by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan. The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $513.6 Million Forecasted Market Value (USD) by 2033 $1542 Million Compound Annual Growth Rate 12.9% Regions Covered Asia Pacific APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges: Market Trends Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring. Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms. Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia. Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput. Market Drivers Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics. Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways. Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines. Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity. Market Challenges High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets. Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches. Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout. Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns. Market Segmentation: Cancer Type Solid Tumors Hematologic Malignancies End User Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes Region Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Molecular Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
8 hours ago
- Yahoo
Scientists develop incredible device that can test for water contamination faster than blink of eye: 'More intelligent'
Scientists develop incredible device that can test for water contamination faster than blink of eye: 'More intelligent' Taking inspiration from the human body, scientists might have cracked the code on how to easily find out if water has been contaminated. According to new research by the National University of Singapore (NUS) covered by Tech Xplore, a new device may be able to vastly improve the way we monitor and manage the quality of our water. Human skin has an oily protective layer known as sebum, which inspired ReSURF, the material invented by the researchers at NUS. Humankind depends on clean water to survive, and ReSURF could be a way to ensure that it becomes more accessible, as well as creating a monitoring method that is kinder to the planet. A thin layer of the ReSURF material covers a sensor, which can analyze and differentiate the electric signals of different types of pollutants in water droplets. Different contaminants create different readings, meaning that scientists can easily identify when water samples are tainted. Associate Professor Benjamin Tee commented per Tech Xplore, "The ReSURF sensor can detect various pollutants, such as oils and fluorinated compounds, which are challenging for many existing sensors." He went on to say that the material is self-powered, self-healing, reusable, and recyclable. Many existing water monitoring systems are pricey, slow, often have limited reusability, and need specialist instruments or bulky lab equipment, according to Tech Xplore. In comparison, ReSURF can detect water pollutants in around 6 milliseconds, which is around 40 times faster than the blink of an eye. While it can be used to monitor water supplies in rivers, lakes, and reservoirs, it can also check on the safety of water in agricultural settings, like rice fields. Beyond that, wastewater management could be revolutionized by using ReSURF monitoring in industrial settings and sewage plants. This will have a major positive impact on making sure access to clean water is more readily available, while also not creating more pollution. Since ReSURF is reusable and recyclable, it is a great example of tech advancements taking the planet into consideration. Professor Tee commented, "We envision this platform as a foundation for the development of more intelligent and responsive water quality monitoring systems." Do you feel safe drinking the tap water where you live? Always Most of the time Not usually Never Click your choice to see results and speak your mind. Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword